Clozapine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Clozapine: From Treatment-Resistant Schizophrenia to Manic Bipolar Affective Disorder
One-Sentence Summary
Clozapine is an atypical antipsychotic agent with a broad receptor-binding profile, established globally as the treatment of choice for treatment-resistant schizophrenia. The TxGNN model predicts it may be effective for Manic Bipolar Affective Disorder, with 6 clinical trials and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Treatment-resistant schizophrenia (globally recognised; no CBG-MEB authorization found in queried database) |
| Predicted New Indication | Manic Bipolar Affective Disorder |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L2 |
| NL Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, Clozapine is a second-generation (atypical) antipsychotic with a uniquely broad receptor-binding profile. It acts as an antagonist at dopamine D2 and D4 receptors, serotonin 5-HT2A receptors, histamine H1 receptors, muscarinic receptors, and adrenergic α1 receptors. This multi-receptor profile distinguishes it from other antipsychotics and underpins its effectiveness in treatment-resistant conditions.
Manic bipolar affective disorder and treatment-resistant schizophrenia share a critical pathophysiological overlap: excessive dopaminergic activity in the mesolimbic pathway. During manic episodes, dopamine hyperactivity drives the core psychomotor agitation, grandiosity, and psychotic features. Clozapine’s D2/D4 antagonism directly suppresses this overactivity, while its 5-HT2A antagonism contributes mood-stabilising effects. The additional α1-adrenergic antagonism provides sedative benefits that are clinically valuable in acute mania management.
The prediction is further supported by a body of clinical evidence: a completed Phase 2 double-blind trial (NCT00029458) directly tested Clozapine in treatment-resistant mania, and a 2020 systematic review with meta-analysis (Delgado et al.) specifically assessed clozapine’s efficacy and adverse effect profile in bipolar disorder. International treatment guidelines already recognise clozapine as an option in treatment-resistant bipolar disorder, making the TxGNN prediction mechanistically coherent and clinically grounded.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00029458 | Phase 2 | Completed | 42 | Double-blind RCT directly evaluating the safety and effectiveness of clozapine for treatment-resistant manic phase of bipolar disorder — the most directly relevant completed trial for this indication |
| NCT05603104 | Phase 3 | Recruiting | 1,254 | Large EU-wide RCT investigating intensified pharmacological treatment after first-line failure in schizophrenia, bipolar depression, and major depressive disorder; results will provide high-quality comparative evidence |
| NCT07047651 | Phase 4 | Recruiting | 40 | Combination of pharmacotherapy with recovery-oriented programmes for treatment-resistant bipolar disorder (RECOVERYTRSBDGR); indirect support for clozapine in bipolar disorder |
| NCT06993662 | Phase 1 | Active, not recruiting | 107 | Combination of pharmacotherapy and individual cognitive behavioural therapy for mental health disorders; primary focus on safety and feasibility |
| NCT03651674 | N/A | Unknown | 200 | MRI neuroimaging study of ECT effects on brain structure and function in schizophrenia and bipolar disorder; provides structural neuroscience context rather than drug efficacy data |
| NCT07398365 | N/A | Recruiting | 100 | Observational phenotyping study of NHS General Adult Psychiatry inpatients; characterises morbidity in the relevant patient population |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32182485 | 2020 | Systematic Review + Meta-analysis | Journal of Psychiatric Research | Directly assessed clinical efficacy and adverse effect profile of clozapine in bipolar disorder — the highest-tier direct evidence for this indication |
| 25346322 | 2015 | Systematic Review | Bipolar Disorders | Evaluated efficacy and safety of clozapine specifically for treatment-resistant bipolar disorder (TRBD); comprehensive evidence synthesis |
| 33719158 | 2021 | Narrative Review | Bipolar Disorders | Comprehensive narrative review of what is known about clozapine in bipolar disorder, current evidence gaps, and future research directions |
| 33460070 | 2020 | Clinical Review / Guideline | Acta Psychiatrica Scandinavica | Evidence-based treatment options for bipolar mania, including recommendations on selection of mood stabilisers and antipsychotics |
| 31488793 | 2019 | Review | Psychiatria Danubina | Explores clozapine’s potential anti-suicidal properties in bipolar disorder, leveraging its unique pharmacological profile and known anti-aggressive effects |
| 37068038 | 2023 | Pharmacoepidemiological Study | Journal of Clinical Psychopharmacology | Asian multicentre prescription pattern study examining clinical characteristics of patients receiving clozapine for bipolar disorder; supports international comparisons |
| 40174308 | 2025 | Retrospective Cohort | Journal of Psychiatric Research | Real-world nationwide study (South Korea) comparing anti-suicidal effectiveness of clozapine, lithium, and valproate in patients with schizophrenia and bipolar disorder |
| 16432528 | 2006 | Review | Molecular Psychiatry | Comprehensive review of treatment-resistant bipolar disorder pharmacotherapy; positions clozapine among second-generation antipsychotics as a therapeutic option |
| 31567198 | 2021 | Clinical Study | American Journal of Therapeutics | Discusses rapid clozapine titration challenges in both schizophrenia and bipolar disorder; directly relevant to clinical implementation and dosing strategy |
| 34787653 | 2022 | RCT (Lithium comparator) | JAMA Psychiatry | RCT on lithium for suicide prevention in bipolar disorder and major depression; provides comparative context for evaluating clozapine’s anti-suicidal role in bipolar disorder |
Netherlands Market Information
No CBG-MEB marketing authorizations for Clozapine were found in the queried database, and the market status is recorded as “not marketed” (未上市).
Note for Dutch prescribers: This result may reflect a data gap in the queried source rather than the complete regulatory picture. Clozapine products may be available in the Netherlands under EMA centrally authorised procedures or via national hospital supply channels. Please verify current authorisation status directly with the CBG-MEB (College ter Beoordeling van Geneesmiddelen) or the EMA medicines database before drawing regulatory conclusions. The SmPC (Samenvatting van de Productkenmerken) should be consulted for the definitive approved indication and prescribing conditions.
Safety Considerations
Please refer to the SmPC (Samenvatting van de Productkenmerken) for complete safety information, as no warnings, contraindications, or drug interaction data were available in this evidence pack.
Practical alert for Dutch prescribers: Clozapine carries well-documented serious risks (including agranulocytosis) that require mandatory haematological monitoring programmes under current European prescribing regulations. The European Clozapine Task Force (Verdoux et al., European Psychiatry, 2025) has recently issued a joint expert statement calling for revision of monitoring rules given significant underuse across Europe. Any prescribing decision for a new indication must be accompanied by a formal monitoring plan per the applicable SmPC and CBG-MEB requirements.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A systematic review with meta-analysis and a completed Phase 2 double-blind trial directly support clozapine’s efficacy in bipolar disorder and treatment-resistant mania. The mechanistic rationale — D2/D4 and 5-HT2A antagonism targeting dopaminergic hyperactivity — is well-established, and clozapine is already referenced in international guidelines as an off-label option for treatment-resistant bipolar disorder.
To proceed, the following is needed:
- Obtain the full EMA or CBG-MEB SmPC for Clozapine to verify approved indications, contraindications, and the required haematological monitoring protocol
- Confirm current CBG-MEB registration status and product availability in the Netherlands, as the queried regulatory database returned zero results (possible data gap)
- Establish a mandatory white blood cell and absolute neutrophil count monitoring programme as required under clozapine prescribing conditions
- Conduct a formal risk-benefit assessment for the target population (treatment-resistant manic bipolar disorder), given clozapine’s serious adverse effect profile
- Define patient selection criteria consistent with “treatment-resistant” designation (minimum two prior adequate pharmacotherapy trials)
- Consider pharmacovigilance plan aligned with CBG-MEB and EMA post-marketing requirements for off-label use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.